New Chinese investigator-initiated trial (IIT) rules are expected to reduce so-called “gray market” activity by tightening oversight while legitimizing pathways for modalities beyond cell and gene therapies. The policy shift is framed as a move toward more formal control of trial conduct and regulatory accountability. For developers outside the traditional cell-and-gene space, the rules may broaden operational clarity for sponsors using IIT mechanisms across additional therapeutic categories. The document also signals that national regulators are aligning clinical research governance with international expectations for trial oversight. In practical terms, biotech partnerships and investment strategies that rely on IIT structures may need operational adjustments to maintain compliance as the effective framework changes.